Response to Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin a randomized study over 21 months 英文参考文献.docVIP

Gonzalez-Gay et al. Arthritis Research Therapy 2011,13:404 /content/13/2/404 LETTER Response to ‘In? iximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomized study over 21 months’ Miguel A Gonzalez-Gay , Carlos Gonzalez-Juanatey , Jose A Miranda-Filloy , Javier Martin , Maria T Garcia-Unzueta ?1 2 3 4 5 and Javier Llorca* ?6,7 See related research by Engvall et al., /content/12/5/R197 We read with great interest the study by Engvall and P-selectin concentrations (r = ?0.513; P = 0.002) [3]. colleagues [1] in a recent issue of Arthritis Research How ever, ghrelin concentrations were not related to the erapy e study showed that anti-tumor necrosis DAS28 (disease activity score using 28 joint counts), the factor-alpha (anti-TNF-α) in? iximab therapy is associa- mean erythrocyte sedimentation rate (ESR), and C- ted with an increase of body fat mass in early rheumatoid arthritis (RA) independently of changes in disease activity and levels of leptin and adiponectin. reactive protein (CRP) from disease diagnosis or the ESR, platelet count, CRP, or cumulative prednisone dose at the time of the study [3]. Moreover, we observed a signi? cant correlation between leptin levels and body mass index [4 ]. With respect to this, we have prospectively followed a cohort of patients who had RA refractory to conventional disease-modifying antirheumatic drugs, including metho- trexate, and who, owing to disease severity, underwent Apart from stimulating growth hormone production, ghrelin regulates energy homeostasis through in